METABOLIC SYNDROME: INSIGHT INTO THE PROBLEM
DOI:
https://doi.org/10.11603/1811-2471.2024.v.i1.14523Keywords:
arterial hypertension, dyslipidemia, ezetimibe, insulin resistance, metformin, obesityAbstract
SUMMARY. The study represents review of modern scientific knowledge on prevalence of the metabolic syndrome worldwide, its role in the pathogenesis of cardiovascular pathology, type 2 diabetes mellitus and possibilities of behavioral and pharmacological modification of its separate components.
The aim – to analyze the evidence of metabolic syndrome formation and development, means of its modification.
Material and Methods. Systematic review and bibliometric analysis of the data, obtained from the available scientific publications, was carried out.
Results. Over the past decades there has been a steady increase in the prevalence of obesity, type 2 diabetes, cardiovascular disease. Metabolic disorders, that occur due to hypodynamia, high-calorie diet, chronic stress, are diagnosed in approximately one third of the world’s population and considered the epidemic of the 21st century. Around 85 % of patients with type 2 diabetes have metabolic syndrome and, thus, higher risks of cardiovascular disease. Modification of different signs of metabolic syndrome has a positive effect on cardiovascular morbidity and mortality, increasing the duration and quality of life of such patients.
Conclusions. Despite the substantial literature data and considerable results of clinical studies of metabolic syndrome, mortality rates from cardiovascular complications among such patients remain high. This indicates the need for further study of this problem, search for opportunities for its early detection and prevention, effective treatment.
References
Henefeld, M., & Leonhardt, W. (1980). Das metabolische Syndrome. Ges. Wes., 36, 545-551.
Reaven, G.M. (1988). Banting lecture 1988. Role of insulin resistance in human disease. Diabetes, 37(12), 1595-607. DOI: 10.2337/diab.37.12.1595.
Haffner, S.M., Miettinen, H., Gaskill, S.P., & Stern, M.P. (1996). Decreased insulin action and insulin secretion predict the development of impaired glucose tolerance. Diabetologia, 39(10), 1201-7. DOI: 10.1007/BF02658507.
Howard, G., O’Leary, D.H., Zaccaro, D., Haffner, S., Rewers, M., Hamman, R., & Bergman, R. (1996). Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation, 93(10), 1809-1817. DOI: 10.1161/01.cir.93.10.1809.
Kaplan, N.M. (1989). The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch. Intern. Med., 149, 1514-1520.
Noubiap, J.J., Nansseu, J.R., Lontchi-Yimagou, E., Nkeck, J.R., Nyaga, U.F., Ngouo, A.T., & Bigna, J.J. (2022). Global, regional, and country estimates of metabolic syndrome burden in children and adolescents in 2020: a systematic review and modelling analysis. Lancet Child Adolesc. Health, 6(3), 158-170. DOI: 10.1016/S2352-4642(21)00374-6.
Pammer, L.M., Lamina, C., Schultheiss, U.T., Kotsis, F., Kollerits, B., Stockmann, H., & GCKD Investigators (2021). Association of the metabolic syndrome with mortality and major adverse cardiac events: A large chronic kidney disease cohort. J. Intern. Med., 290, 1219-1232. DOI: 10.1111/joim.13355.
Tracy, B.M., Wilson, J.M., Staley, C., Frias, B., Schenker, M.L., & Gelbard, R.B. (2020). Metabolic Syndrome: Major Risk Factor for Morbidity and Mortality in Severely Injured Trauma Patients. J. Am. Coll. Surg., 230(1), 145-150. DOI: 10.1016/j.jamcollsurg.2019.09.009.
Noubiap, J.J., Nansseu, J.R., Lontchi-Yimagou, E., Nkeck, J.R., Nyaga, U.F., Ngouo, A.T., & Bigna, J.J. (2022). Geographic distribution of metabolic syndrome and its components in the general adult population: A meta-analysis of global data from 28 million individuals. Diabetes Research and Clinical Practice, 188. DOI: 10.1016/j.diabres. 2022.109924.
Saklayen, M.G. (2018). The Global Epidemic of the Metabolic Syndrome. Curr. Hypertens. Rep., 20(2), 12. DOI: 10.1007/s11906-018-0812-z.
Farmanfarma, K., Ansari-Moghaddam, A., Kaykhaei, M., Mohammad, M., Adineh, H., & Aliab, H. (2021). Incidence of and factors associated with metabolic syndrome, south-east Islamic Republic of Iran. East Mediterr. Health J., 27(11), 1084-1091. DOI: 10.26719/emhj.21.051.
Tolstikova, O.O., & Aharkov, S.F. (2019). Suchasni pohlyady na metabolichnyy syndrom u ditey ta pidlitkiv [Modern views on metabolic syndrome in children and adolescents]. Lik. sprava – Medical case, 5-6, 27-29. DOI: 10.31640/JVD.5-6.2019(3) [in Ukrainian].
Reisinger, C., Nkeh-Chungag, B.N., Fredriksen, P.M., & Goswami, N. (2021). The prevalence of pediatric metabolic syndrome—a critical look on the discrepancies between definitions and its clinical importance. Int. J. Obes., 45, 12-24. DOI: 10.1038/s41366-020-00713-1.
Ye, Y., Zhou, Q., Dai, W., Peng, H., Zhou S., Tian, H., Shen, L., & Han, H. (2023). Gender differences in metabolic syndrome and its components in southern china using a healthy lifestyle index: a cross-sectional study. BMC Public Health, 23, 686. DOI: 10.1186/s12889-023-15584-0.
Dev, R., Behlouli, H., Parry, M., Raparelli, V., Norris, C.M., & Pilote, L. (2023). Impact of Sex and Gender on Metabolic Syndrome in Adults: A Retrospective Cohort Study From the Canadian Primary Care Sentinel Surveillance Network. Can. J. Diabetes. DOI: 10.1016/j.jcjd.2023. 08.008.
Tian, X., Xu, X., Zhang, K., & Wang, H. (2017). Gender difference of metabolic syndrome and its association with dietary diversity at different ages. Oncotarget, 8, 73568-73578. DOI: 10.18632/oncotarget.20625.
Cherniavska, I.V., & Mykytiuk M.R. (2021). Menopauzalnyy metabolichnyy syndrom: pohlyad endokrynoloha [Menopausal metabolic syndrome: an endocrinologist’s view]. Problemy endokrynnoyi patolohiyi – Problems of endocrine pathology, 76(2), 117-125. DOI: 10.21856/j-PEP. 2021.2.16 [in Ukrainian].
Zhang, C., Zhao, M., Li, Z., & Song, Y. (2020). Follicle-Stimulating Hormone Positively Associates with Metabolic Factors in Perimenopausal Women. Int. J. Endocrinol., 2020. DOI: 10.1155/2020/7024321.
Jha, B.K., Sherpa, M.L., Imran, M., Mohammed, Y., Jha, L.A., Paudel, K.R., & Jha, S.K. (2023). Progress in Understanding Metabolic Syndrome and Knowledge of Its Complex Pathophysiology. Diabetology, 4(2), 134-159. DOI: 10.3390/diabetology4020015.
Li, W., Chen, D., Peng, Y., Lu, Z., Kwan, M.P., & Tse, L.A. (2023). Association Between Metabolic Syndrome and Mortality: Prospective Cohort Study. JMIR Public Health Surveill., 9. DOI: 10.2196/44073.
Mazloomzadeh, S., Karami Zarandi, F., Shoghli, A., & Dinmohammadi, H. (2019). Metabolic syndrome, its components and mortality: A population-based study. Med. J. Islam Repub. Iran, 33, 11. DOI: 10.34171/mjiri.33.11.
Kohansal, K., Masrouri, S., Khalili, D., Ramezankhani, A., Azizi, F., Blaha, M.J., & Hadaegh, F. (2022). Changes in Fasting plasma glucose status and risk of mortality events in individuals without diabetes over two decades of Follow-up: a pooled cohort analysis. Cardiovasc. Diabetol., 21, 267. DOI: 10.1186/s12933-022-01709-z.
Health Index. Ukraine-2019: Results national research. (2020). Retrieved from: http://health-index.com.ua/HI_Report_2019_Preview.pdf.
Han, T.S., & Lean, M.E. (2016). A clinical perspective of obesity, metabolic syndrome and cardiovascular disease. JRSM Cardiovasc. Dis., 5. DOI: 10.1177/2048004016633371.
Damiri, B., Abualsoud, M.S., Samara, A.M., & Salameh, S.K. (2018). Metabolic syndrome among overweight and obese adults in Palestinian refugee camps. Diabetol. Metab. Syndr., 10, 34. DOI: 10.1186/s13098-018-0337-2.
Nilsson, P.M., Tuomilehto, J., & Rydén, L. (2019). The metabolic syndrome – What is it and how should it be managed? European Journal of Preventive Cardiology, 26 (2), 33-46. DOI: 10.1177/2047487319886404.
Díaz-Ortega, J.L., Yupari-Azabache, I.L., Caballero Vidal, J.A., Conde-Parada, N.E., & Rojas Gamboa, A.F. (2023). Criteria in the Diagnosis of Metabolic Syndrome in Children: A Scoping Review. Diabetes Metab. Syndr. Obes., 16, 3489-3500. DOI: 10.2147/DMSO.S430360.
Alberti, K.G., & Zimmet, P.Z. (1998). Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med., 15(7), 539-553. DOI: 10.1002/(SICI)1096-9136 (199807) 15:7<539:AID-DIA668>3.0.CO;2-S.
National Institutes of Health: Executive summary (2001). In Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Washington, DC, U.S. Govt. Printing Office, NIH publ. no. 01-3670.
International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome. Retrieved from: http://www.idf.org/webdata/docs/Metabolic_syndrome_definition.pdf.
Spencer, C.P., Godsland, I.F., & Stevenson, J.C. (1997). Is there a menopausal metabolic syndrome? Gynecol. Endocrinol., 11(5), 341-355. DOI: 10.3109/09513599709152559.
Fonseca, É.J.N. da C., Rocha, T.P.O., Nogueira, I.A.L., de Melo, J.B., de Silva, B.L., Lopes, E.J., Serra, C.B., Andrade, M.V.G., de Sousa, S.M.B., & de Figueredo Neto, J.A. (2018). Metabolic Syndrome and Insulin Resistance by HOMA-IR in Menopause. Int. J. of Cardiovasc. Sci., 31(3), 201-208. DOI: 10.5935/2359-4802.20180009.
Zaychenko, G.V., Sinitsyna, O.S., Karpenko, N.O., Rizhenko, I.M., & Striga, O.A. (2019). Disturbances in female health due to age and varying estrogen deficiency levels and their corrections (literature review). Journal of the National Academy of Medical Sciences of Ukraine, 25(2), 211-221.
Nair, A.R., Pillai, A.J., & Nair, N. (2021). Cardiovascular Changes in Menopause. Curr. Cardiol. Rev., 17(4). DOI: 10.2174/1573403X16666201106141811.
Ohmichi, M., Kanda, Y., Hisamoto, K., Morishige, K., Takahashi, K., Sawada, K., & Murata, Y. (2003). Rapid changes of flow-mediated dilatation after surgical menopause. Maturitas, 44(2), 125-131. DOI: 10.1016/s0378-5122(02) 00320-1.
Lakhno, I.V. (2021). Mozhlyvosti vykorystannya preparativ ksylitu ta L-arhininu v vedenni menopauzy [Possibilities of using xylitol and L-arginine drugs in menopause management]. Reproduktyvne zdorovya zhinky – Reproductive Health of Woman, 2(47), 64-68. DOI: 10.30841/2708-8731.2.2021.232554 [in Ukrainian].
Hamoda, H., Panay, N., Pedder, H., Arya, R., & Savvas, M. (2020). The British Menopause Society & Women’s Health Concern 2020 recommendations on hormone replacement therapy in menopausal women. Post Reproductive Health, 26(4), 181-209. DOI: 10.1177/2053369120957514.
Castro-Barquero, S., Ruiz-León, A.M., Sierra-Pérez, M., Estruch, R., & Casas, R. (2020). Dietary Strategies for Metabolic Syndrome: A Comprehensive Review. Nutrients, 12(10), 2983. DOI: 10.3390/nu12102983.
Nyankovska, O.S., Nyankovskyy, S.L., Yatsula, M.S., & Horodylovska, M.I. (2021). Metabolichnyy syndrom – diyetychni rekomendatsiyi ta nutrytsevtychna korektsiya [Metabolic syndrome – dietery recommendations and nutraceutical correction]. Endokrynolohiya – Endocrinology, 26(4), 396-408. DOI: 10.31793/1680-1466.2021.26-4.396 [in Ukrainian].
Åberg, F., Byrne, C.D., Pirola, C.J., Männistö, V., & Sookoian, S. (2023). Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease. J. Hepatol., 78(1), 191-206. DOI: 10.1016/j.jhep. 2022.08.030.
Artese, A., Stamford, B.A., & Moffatt, R.J. (2017). Cigarette Smoking: An Accessory to the Development of Insulin Resistance. Am. J. Lifestyle Med., 13(6), 602-605. DOI: 10.1177/1559827617726516.
Graff-Iversen, S., Hewitt, S., Forsén, L., Grøtvedt, L., & Ariansen, I. (2019). Associations of tobacco smoking with body mass distribution; a population-based study of 65,875 men and women in midlife. BMC Public Health, 19, 1439. DOI: 10.1186/s12889-019-7807-9.
Mostafa, S., Shalaby, M., El-Shiekh, R., Elbanna, H., Emam, S., & Bakr, A. (2023). Metabolic syndrome: risk factors, diagnosis, pathogenesis, and management with natural approaches. Food Chem. Adv., 3, 100335. DOI: 10.1016/j.focha.2023.100335.
Visseren, F.L.J., Mach, F., Smulders, Y.M., Carballo, D., Koskinas, K.C., & Bäck, M. (2022). ESC Scientific Document Group. 2021. ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur. J. Prev. Cardiol., 29, 5-115. DOI: 10.1093/eurjpc/zwab154.
Diabetes Prevention Program (DPP) Research Group. (2002). The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care, 25(12), 2165-2171. DOI: 10.2337/diacare.25.12.2165.
Lima, L.M., Wiernsperger, N., Kraemer-Aguiar, L.G., & Bouskela, E. (2009). Short-term treatment with metformin improves the cardiovascular risk profile in first-degree relatives of subjects with type 2 diabetes mellitus who have a metabolic syndrome and normal glucose tolerance without changes in C-reactive protein or fibrinogen. Clinics (Sao Paulo), 64(5), 415-420. DOI: 10.1590/s1807-59322009000500008.
King, P., Peacock, I., & Donnelly, R. (1999). The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br. J. Clin. Pharmacol., 48 (5), 643-648. DOI: 10.1046/j.1365-2125.1999.00092.x.
Jang, A.Y., Lim, S., Jo, S.H., Han, S.H., & Koh, K.K. (2021). New Trends in Dyslipidemia Treatment. Circ. J., 85(6), 759-768. DOI: 10.1253/circj.CJ-20-1037.
Lee, Y.J., Lee, S.H., You, S.C., Lee, Y.H., Lee, S.J., Hong, S.J., … Kim, J.S. (2023). Moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with metabolic syndrome and atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING trial. Diabetes Obes. Metab., 26(3), 829-839. DOI: 10.1111/dom.15374.
Bach, R.G., Cannon, C.P., Giugliano, R.P., White, J.A., Lokhnygina, Y., Bohula, E.A., Califf, R.M., Braunwald, E., & Blazing, M.A. (2019). Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol., 4(9), 846-854. DOI: 10.1001/jamacardio.2019.2306.
Dec, A., Niemiec, A., Wojciechowska, E., Maligłówka, M., Bułdak, Ł., Bołdys, A., & Okopień, B. (2023). Inclisiran-A Revolutionary Addition to a Cholesterol-Lowering Therapy. Int. J. Mol. Sci., 24 (7), 6858. DOI: 10.3390/ijms24076858.
Olagunju, A., Yamani, N., Kenny, D., Mookadam, M., Mookadam, F., & Unzek, S. (2022). Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis. World J. Cardiol., 14 (11), 599-616. DOI: 10.4330/wjc.v14.i11.599.
Wang, X., Wu, N., Sun, C., Jin, D., & Lu, H. (2023). Effects of SGLT-2 inhibitors on adipose tissue distribution in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Diabetol. Metab. Syndr., 15(1), 113. DOI: 10.1186/s13098-023-01085-y.
Sanz-Cánovas, J., Ricci, M., Cobos-Palacios, L., López-Sampalo, A., Hernández-Negrín, H., Vázquez-Márquez, M., … Bernal-López, M.R. (2023). Effects of a New Group of Antidiabetic Drugs in Metabolic Diseases. Rev. Cardiovasc. Med., 24(2), 36. DOI: 10.31083/j.rcm2402036.
Matthews, J., Herat, L., Schlaich, M.P., & Matthews, V. (2023). The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status. Int. J. of Mol. Sci., 24 (18), 14243. DOI: 10.3390/ijms241814243.
Gulinac, M., Miteva, D.G., Peshevska-Sekulovska, M., Novakov, I.P., Antovic, S., Peruhova, M., … Velikova, T. (2023). Long-term effectiveness, outcomes and complications of bariatric surgery. World J. Clin. Cases, 11(19), 4504-4512. DOI: 10.12998/wjcc.v11.i19.4504.
